3,200 press releases indexed under healthcare.
First 24 Hours of Performance Ads Match Lifetime Downloads - Positioning for Accelerated Consumer Growth
(PR-inside.com) Funds Advance FDA-Designated Breakthrough Therapy First-in-Class Opioid with Oral Overdose-Protection SAN DIEGO, CA / ACCESS Newswire / July 14, 2026 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics engineered to minimize abuse and overdose risk, today announced receipt of a Notice of Award for $5.3 million from the National Institutes on Drug Abuse (NIDA)1 to support the development of its novel MPAR® (Multi-Pill Abuse Resistance) overdose-protection technology, and the lead agent, PF614-MPAR. This marks the third consecutive year of NIDA funding under this award, reflecting sustained institutional confidence in ..
(PR-inside.com) 97% of Surveyed Injection Users Would Consider Pump Therapy - if Easier to Learn and Improved Outcomes Conducting Additional Research Initiative in Conjunction with Commercialization of the Pivot Tubeless Insulin Patch Pump Company to Showcase Pivot at Association of Diabetes Care & Education Specialists (ADCES) Annual Conference, August 7-10, 2026 SAN DIEGO, CA / ACCESS Newswire / July 14, 2026 / Modular Medical, Inc. ("Modular Medical" or "the Company") (NASDAQ:MODD), a commercial-stage medical device company that is commercializing the next generation of insulin delivery technology, today announced positive findings from a new comprehensive diabetes patient research initiative further supporting its commercialization strategy. The ..
Funds Advance FDA-Designated Breakthrough Therapy First-in-Class Opioid with Oral Overdose-Protection
ESS has launched ESS Clinical MSP, a Managed Service Provider program that helps K-12 school districts simplify the management of clinical and related services. The program serves as a single point of contact for sourcing licensed specialists, coordinating vendors, tracking credentials...
97% of Surveyed Injection Users Would Consider Pump Therapy - if Easier to Learn and Improved Outcomes Conducting Additional Research Initiative in Conjunction with Commercialization of the Pivot Tubeless Insulin Patch Pump Company to Showcase Pivot at Association of Diabetes Care & Education Specialists (ADCES) Annual Conference, August 7-10, 2026
Launching in New York, San Francisco, and Los Angeles, SONATA combines deep clinical testing, dedicated physicians, and clinical AI to help members build a fuller picture of their health and take action before disease starts. NEW YORK, July 14, 2026 /PRNewswire/ -- SONATA, offering a...
Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation planned 2H 2026
BLAINVILLE, QC, July 14, 2026 /PRNewswire/ - Médunik Canada, a Canadian owned and operated pharmaceutical company dedicated to improving the health and quality of life of people living with rare and debilitating diseases, part of Duchesnay Pharmaceutical Group, is pleased to announce that...
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
Expanded program increases access to care, strengthens local health systems across more than 40 hospitals nationwide SAN JOSE, Calif., July 14, 2026 /PRNewswire-PRWeb/ -- Fistula Foundation today announced impressive, countrywide results one year into an expanded effort to reach women...
Updated NCCN language continues to support CSF analysis in the diagnosis and management of leptomeningeal metastases, including CSF cytology follow-up every 4 to 8 weeks for patients receiving intrathecal therapy, to enable longitudinal patient monitoring Updated NCCN language continues to support CSF analysis in the diagnosis and management of leptomeningeal metastases, including CSF cytology follow-up every 4 to 8 weeks for patients receiving intrathecal therapy, to enable longitudinal patient monitoring